Regulatory GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug BioSpaceJideytro is GSK's first approved product for lung cancer.OncologyRead full story pharminent July 23, 2026 (Last updated: July 23, 2026) BioSpace Jideytro is GSK’s first approved product for lung cancer. Oncology Read full story Post navigation Previous: Arrowhead’s Plozasiran Cuts Triglycerides Roughly 80% in Two Phase 3 TrialsNext: Lilly plans Q1 2027 filing for obesity triple retatrutide Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026